TargetMol Chemicals Inc.회사는 제품 목록을 제공합니다.
회사 명:
TargetMol Chemicals Inc.
전화:
-
이메일:
marketing@targetmol.com
국적:
China
URL:
https://www.targetmol.cn/
총 제품 수:
28091
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
제품 카탈로그
Sodium 2-oxopropanoate;Sodium pyruvate
피루브 산, 나트륨 염
113-24-6
C3H5NaO3
Palivizumab;Synagis|||MEDI 493
팔리비주맙
188039-54-5
Astegolimab;RG 6149|||MSTT 1041A
2173054-79-8
Efalizumab;Hu1124|||HU 1124
에팔리주마붐
214745-43-4
Bersanlimab;BI-505
1987854-08-9
Burfiralimab;hzVSF-v13
2460809-80-5
Carotuximab;
1268714-50-6
Vixarelimab;
2243320-83-2
Belimumab;LymphoStat B
벨리무맙
356547-88-1
Tomaralimab;OPN-305
1449294-76-1
Siltuximab;CNTO-328
541502-14-1
Suptavumab;REGN2222
1629615-23-1
Felzartamab;TJ-202|||MOR-03087|||MOR-202
2197112-39-1
Flanvotumab;20D7S|||IMC 20D7S
1188277-05-5
Garadacimab;CSL312
2162134-62-3
Garetosmab;
2097125-54-5
Aducanumab;
아두카누맙
1384260-65-4
Itepekimab;REGN-3500|||SAR-440340
2226742-52-3
Latozinemab;GSK-4527223|||AL-001
2376132-27-1
Lecanemab;BAN-2401
1260393-98-3
Leronlimab;
674782-26-4
Spartalizumab;PDR001
1935694-88-4
Nadecnemab;REGN-5069
2377679-19-9
Theralizumab;
906068-56-2
Sibrotuzumab;BIBH 1|||Anti-Human FAP Recombinant Antibody
216669-97-5
Ulocuplumab;BMS 936564|||MDX 1338
1375830-34-4
Xentuzumab;BI 836845
1417158-65-6
Patritumab;
1262787-83-6
GSNKGAIIGLM(131602-53-4(free base));Amyloid beta-peptide(25-35)
131602-53-4
C45H81N13O14S
FG-3019;
946415-13-0
Ganitumab;AMG 479
905703-97-1
Lexatumumab;ETR2-ST01|||DR5 mAB|||HGS-ETR 2
렉사투무맙
845816-02-6
Sonepcizumab;LT 1009
1031360-18-5
Teneliximab;Chi220|||Anti-Human CD40 Recombinant Antibody|||BMS 224819
299423-37-3
Nimacimab;JNJ 2463|||RYI-018
2098636-09-8
Nirsevimab;
1989556-22-0
Plozalizumab;
1610761-46-0
Praluzatamab;
2145109-70-0
Osocimab;BAY 1213790
2056878-75-0
Otilimab;GSK 3196165|||MOR103
1638332-55-4
Belantamab;GSK2857914
2061894-48-0
Clesrovimab;MK-1654
2429913-18-6
Tafasitamab;MOR00208|||XmAb5574|||Tafasitamab-cxix
1422527-84-1
Ragifilimab;INCAGN-01876|||INCAGN-1876|||CM-701
2207590-51-8
Cobolimab;
2022215-65-0
UK 088800;
139756-21-1
C17H20N4O2
Tesidolumab;LFG316
1531594-08-7
Abciximab;C7E3
압식시맙
143653-53-6
Andecaliximab;GS-5745
1518996-49-0
Anetumab;
1954758-84-9
Ascrinvacumab;PF-03446962
1463459-96-2
Ramiprilat;
라미프리랏
87269-97-4
C21H28N2O5
Cinpanemab;BIIB054
2094516-02-4
Elezanumab;AE12-1Y-QL|||ABT-555
1791416-49-3
Enapotamab;
1912423-61-0
Icrucumab;LY 3012212|||IMC-18F1
1024603-92-6
Ravulizumab;ALXN1210
1803171-55-2
Narsoplimab;OMS 721
2108782-45-0
Nidanilimab;
2171061-85-9
Erenumab;AMG-334
1582205-90-0
Vofatamab;RG-7444|||B-701|||MFGR-1877S
1312305-12-6
Talquetamab;JNJ-64407564|||JNJ-7564
2226212-40-2
Talacotuzumab;CSL 362|||JNJ 56022473
1826831-79-1
Spesolimab;BI 655130
2097104-58-8
Donanemab;
1931944-80-7
Quetmolimab;E-6011|||KANAb 001
2084037-83-0
Petosemtamab;MCLA 158
2213450-26-9
Oxelumab;Ro 49-89991|||R 4930|||huMAb OX 40L
1186098-83-8
Ordesekimab;AMG 714|||PRV-015
879293-15-9
Abrezekimab;UCB4144|||VR 942
2043952-59-4
Siplizumab;MEDI-507
288392-69-8
Clivatuzumab;
1622075-09-5
D-Ribose 5-phosphate disodium dihydrate;
207671-46-3
C5H9Na2O8P2H2O
Mannan;
만난
9036-88-8
ACEPROMAZINE MALEATE;
3598-37-6
C23H26N2O5S
DSPE-NHS;
1383932-86-2
C49H89N2O13P
TV 3279;
209394-29-6
C16H20N2O2
(Iso)-BMT-124110 Formate;(R)-N-(8-((2-amino-2,4-dimethylpentyl)oxy)-5H-chromeno[3,4-c]pyridin-2-yl)acetamide Formate(1679370-98-9 Free base)
HDAC-IN-57;
2716217-79-5
C21H19N3O4
PLH1215;
1332084-64-6
PLH2058;
2525206-41-9
BRD4-IN-4;
304685-40-3
C17H18N2O3S
AB21 HCl;
icFSP1;
1115910-36-5
2-aminobenzo[d]thiazol-6-ol;
2-아미노-벤조티아졸-6-OL
26278-79-5
C7H6N2OS
2-Amino-6-bromopyridine;
19798-81-3
C5H5BrN2
Butylboronicacid;
4426-47-5
C4H11BO2
CCR1/5/8 activator 1;
7-메틸린돌-3-카르복스알데하이드
4771-50-0
C10H9NO
5-Nitro-1,10-phenanthroline;5-NP
4199-88-6
C12H7N3O2
tert-Butyl5-bromo-1H-indole-1-carboxylate;N-Boc-5-bromoindole
TERT-BUTYL5-브로모인돌-1-카복실레이트
182344-70-3
C13H14BrNO2
ACHE Inhibitor 12;
1H-인덴-1-온,2,3-디하이드로-2,6-디메틸-
66309-83-9
C11H12O
MyD88-IN-1;
2911609-80-6
C23H24N6O7S
Tezepelumab;Tezepelumab-ekko|||MEDI 19929|||AMG 157
테제펠루맙
1572943-04-4
Vorsetuzumab;SGN-70
1165740-62-4
Sibeprenlimab;
2382896-07-1
Urelumab;BMS-663513|||BMS-66513
934823-49-1
Telazorlimab;ISB-830|||GBR-830
2126777-87-3
Ianalumab;VAY-736
1929549-92-7
Tisotumab;1E10|||1.00E+10
1418628-81-5
Concizumab;mAb 2021|||NN 7415
1312299-39-0
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
Copyright 2019 © ChemicalBook. All rights reserved